Hypopituitarism in PHACES association

Pediatric Dermatology

Volumn 23, Issue 5, 2006, Pages 476-480

  Goddard, Deborah S ^a   Liang, Marilyn G ^a   Chamlin, Sarah L ^b   Svoren, Britta M ^a   Spack, Norman P ^a   Mulliken, John B ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; CARBIDOPA PLUS LEVODOPA; CORTICOSTEROID; GLUCAGON; GROWTH HORMONE; PREDNISOLONE; SOMATOMEDIN C;

ARTICLE; CASE REPORT; CAUCASIAN; CLINICAL FEATURE; DEVELOPMENTAL DISORDER; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; EMPTY SELLA SYNDROME; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH RETARDATION; HEMANGIOMA; HUMAN; HYPOPITUITARISM; INFANT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHACES SYNDROME; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROVOCATION TEST; PULSED DYE LASER; SYNDROME; TREATMENT WITHDRAWAL;

CENTRAL NERVOUS SYSTEM VASCULAR MALFORMATIONS; CRANIAL FOSSA, POSTERIOR; EYE ABNORMALITIES; FACIAL NEOPLASMS; FEMALE; HEART DEFECTS, CONGENITAL; HEMANGIOMA; HUMANS; HYPOPITUITARISM; INFANT, NEWBORN; SKIN NEOPLASMS; STERNUM; SYNDROME;

EID: 33646085476     PISSN: 07368046     EISSN: 15251470     Source Type: Journal    
DOI: 10.1111/j.1525-1470.2006.00287.x     Document Type: Article

References (23)

1. Frieden IJ, Reese V, Cohen D. PHACE syndrome. The association of posterior fossa brain malformations, hemangiomas, arterial anomalies, coarctation of the aorta and cardiac defects, and eye abnormalities. Arch Dermatol 1996;132:307-311.
2. Lasky J, Sandu M, Balashanmugan A. PHACE syndrome: association with persistent fetal vasculature and coloboma-like iris defect. J AAPOS 2004;8:495-498.
3. Metry DW, Dowd CF, Barkovich AJ et al. The many faces of PHACE syndrome. J Pediatr 2001;139:117-123.
4. Poetke M, Frommeld T, Berlien HP. PHACE syndrome: new views on diagnostic criteria. Eur J Pediatr Surg 2002;12:366-374.
5. Luo CB, Lasjaunias P, Teng MM et al. Cervico-cerebrovascular anomalies in children with PHACE syndrome. J Formos Med Assoc 2003;102:379-386.
6. Coats DK, Paysse EA, Levy ML. PHACE, a neurocutaneous syndrome with important ophthalmologic implications: case report and literature review. Ophthalmology 1999;106:1739-1741.
7. Geller JD, Topper SF, Hashimoto K. Diffuse neonatal hemangiomatosis: a new constellation of findings. J Am Acad Dermatol 1991;24:816-818.
8. Pascual-Castroviejo I, Viaño J, Moreno F et al. Hemangiomas of the head, neck, and chestwith associated vascular and brain anomalies: a complex neurocutaneous syndrome. Am J Neuroradiol 1996;17:461-471.
9. Grosso S, De Cosmo L, Bonifazi E et al. Facial hemangioma and malformation of the cortical development: a broadening of the PHACE spectrum or a new entity? Am J Med Genet 2004;124A:192-195.
10. Kronenberg A, Blei F, Ceisler E et al. Ocular and systemic manifestations of PHACES (posterior fossa malformations, hemangiomas, arterial anomalies, cardiac defects and coarctation of the aorta, eye abnormalities, and sternal abnormalities or ventral developmental defects) syndrome. J AAPOS 2005;9:169-173.
11. Burrows PE, Robertson RL, Mulliken JB et al. Cerebral vasculopathy and neurologic sequelae in infants with cervicofacial hemangioma: report of eight patients. Radiology 1998;207:601-607.
12. Brown RS, Demmer LA. The etiology of thyroid dysgenesis - still an enigma after all these years. J Clin Endocrinol Metab 2002;87:4069-4071.
13. Huang SA, Tu HM, Harney JW et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Engl J Med 2000;343:185-189.
14. Greinwald JH Jr, Burke DK, Bonthius DJ et al. An update on the treatment of hemangiomas in children with interferon alfa-2a. Arch Otolaryngol Head Neck Surg 1999;125:21-27.
15. Liberek A, Luczak G, Korzon M et al. Tolerance of interferon-alfa therapy in children with chronic hepatitis B. J Paediatr Child Health 2004;40:265-269.
16. Iorio R, Pensati P, Botta S et al. Side effects of alfa-interferon therapy and impact on health-related quality of life in children with chronic viral hepatitis. Pediatr Infect Dis J 1997;16:984-990.
17. Traggiai C, Stanhope R. Endocrinopathies associated with midline cerebral and cranial malformations. J Pediatr 2002;140:252-255.
18. Allen DB, Mullen M, Mullen B. A meta-analysis of the effects of oral and inhaled glucocorticoids on growth. J Allergy Clin Immunol 1994;93:967-976.
19. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metab Clin North Am 1996;25:699-717.
20. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999;104:1616-1623.
21. Blei F, Chianese J. Corticosteroid toxicity in infants treated for endangering hemangiomas: experience and guidelines for monitoring. Int Pediatr 1999;14:146-153.
22. Simon D, Fernando C, Czernichow P et al. Linear growth and final height in patientswith systemic idiopathic arthritis treated with long-term glucocorticoids. J Rheumatol 2002;29:1296-1300.
23. Gafni RI, Weise M, Robrecht DT et al. Catch-up growth is associated with delayed senescence of growth plate in rabbits. Pediatr Res 2001;50:618-623.